<DOC>
	<DOCNO>NCT00016432</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use exemestane may fight breast cancer reduce production estrogen tumor cell . It yet know whether exemestane effective preventing recurrence breast cancer . PURPOSE : Randomized phase III trial study effectiveness exemestane prevent cancer recurrence postmenopausal woman resect stage I , stage II , stage IIIA breast cancer complete 5 year tamoxifen .</brief_summary>
	<brief_title>Exemestane Treating Postmenopausal Women With Resected Stage I , Stage II , Stage IIIA Breast Cancer Who Have Completed 5 Years Tamoxifen</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether administration 5 year exemestane 5 year tamoxifen therapy effective 5 year prior tamoxifen therapy alone prolong disease-free survival , overall survival , time treatment failure postmenopausal woman resect stage I , II , IIIA breast cancer . - Determine effect tamoxifen withdrawal bone , term height , fracture , total alkaline phosphatase patient bone mineral density bone biochemical marker subset patient . - Determine effect exemestane bone loss tamoxifen withdrawal patient . - Evaluate quality life subset patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral exemestane daily 5 year . - Arm II ( close 10/15/03 ) : Patients receive oral placebo daily 5 year . Quality life assess baseline every 6 month 5.5 year . Patients follow every 6 month 6 year annually thereafter . PROJECTED ACCRUAL : A total 3,000 patient accrue study within 3 year 4 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive adenocarcinoma breast time original diagnosis Tumor confine breast ipsilateral axilla clinical exam ( T13 , N01 , M0 ) ( stage IIIIA ) No ipsilateral lymph node clinically fix one another structure ( N2 disease ) time original diagnosis Prior surgical resection , include 1 following : Total mastectomy axillary dissection ( modified radical mastectomy ) OR Lumpectomy axillary dissection Prior postlumpectomy breast radiotherapy require Prior sentinel node biopsy allow exception follow : If sentinel node histologically positive hematoxylin eosin ( H &amp; E ) OR histologically suspicious H &amp; E confirm positive immunohistochemistry patient must complete axillary dissection Previously resect margin must clear invasive tumor ductal carcinoma situ Currently disease free Previously treat tamoxifen 5766 month Completed tamoxifen within past 180 day No bilateral malignancy mass opposite breast suspicious malignancy unless biopsy proven negative No local , regional , distant recurrence disease second primary breast malignancy ( include contralateral breast cancer ) No advanced disease time original diagnosis ( e.g. , ulceration , erythema , infiltration skin underlie chest wall [ complete fixation ] , peau d'orange , skin edema magnitude ) Tethering dimple skin nipple inversion allow Current skeletal pain allow bone scan and/or radiologic exam negative metastatic disease Hormone receptor status : Primary tumor estrogen receptor ( ER ) positive AND/OR Progesterone receptor positive Borderline ER positive tumor allow previously treat tamoxifen PATIENT CHARACTERISTICS : Age : Postmenopausal Sex : Female Menopausal status : Postmenopausal , define 1 following : Prior bilateral oophorectomy Absence spontaneous menstrual cycle 1 year Folliclestimulating hormone within postmenopausal range 55 prior hysterectomy without bilateral oophorectomy Performance status : Not specify Life expectancy : At least 10 year Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin normal Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Alkaline phosphatase less 2 time ULN No systemic hepatic disease would preclude study participation Renal : Creatinine great 1.5 time ULN No systemic renal disease would preclude study participation Cardiovascular : No systemic cardiovascular disease would preclude study participation Other : No malignancy within past 5 year except effectively treat squamous cell basal cell skin cancer , surgically treat carcinoma situ cervix , surgically treat lobular carcinoma situ ipsilateral contralateral breast No nonmalignant systemic disease would preclude study participation No psychiatric addictive disorder would preclude informed consent Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior adjuvant chemotherapy allow administer concurrently prior tamoxifen Endocrine therapy : See Disease Characteristics No concurrent estrogen , progesterone , clomiphene , testosterone , gonadotropinreleasing hormone , oral contraceptive , selective estrogenreceptor modulators , dehydroepiandrosterone ( DHEA ) Estring estrogen vaginal cream 0.3 mg 1/8 applicator apply vaginally 3 time week allow No concurrent systemic hormonal therapy ( e.g. , tamoxifen raloxifene ) Radiotherapy : See Disease Characteristics Prior postmastectomy locoregional radiotherapy postlumpectomy regional radiotherapy allow Surgery : See Disease Characteristics Other : Prior participation adjuvant NSABP study allow study report peerreview publication tamoxifen study drug Concurrent bisphosphonates calcitonin prevention treatment osteoporosis allow Concurrent statin ( simvastatin , pravastatin , fluvastatin , atorvastatin , lovastatin ) drug control lipid level allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>